Participated · Series A · Aug 2025

3DC develops and manufactures Graphene MesoSponge® (GMS), a three-dimensional graphene material with porosity, conductivity, flexibility, and corrosion resistance intended to address trade-offs in battery performance. The company was founded in February 2022 and is headquartered at Tohoku University in Sendai, with a Kawasaki office and a pilot factory in Toki, Gifu where construction of the world’s first GMS mass-production facility has begun. Following a Series A 1st-close in August 2025 and ongoing validation work, 3DC is supplying functional conductive additive GMS to numerous domestic and international battery makers for evaluation. 3DC plans to use recent and prior funding to expand its pilot factory into a mass-production plant, establish ton-scale production processes, strengthen global supply for customer evaluations and commercialization, and expand R&D talent and overseas partnerships. The company positions partnerships with established industry players and strategic investors as key to accelerating production, supply-chain stabilization, and market adoption of GMS.

Participated · Series B · Jan 2021

Metcela is a clinical-stage biotechnology company based in Kanagawa, Japan, developing first-in-class autologous cell therapies targeting serious cardiovascular diseases. Established in 2016, the company focuses on fibroblast and stem cell–based therapies for chronic diseases with limited treatment options. Metcela is advancing MTC001, a combination product of autologous cardiac cells (VCAM-1-positive Cardiac Fibroblast, VCF) paired with a novel catheter delivery system for chronic heart failure patients. The company recently closed a $14M Series C financing to support its plans. Proceeds will be used to prepare for commercialization by establishing manufacturing infrastructure, to strengthen new pipeline development capabilities, and to reinforce R&D by expanding research facilities. Metcela is positioning to move its clinical programs toward commercialization while expanding its research and manufacturing capacity. Metcela is a clinical-stage biotech founded in 2016 in Kanagawa, Japan, focused on developing fibroblast-based therapies for chronic diseases with limited options. Its lead asset, MTC001, is a VCAM-1-positive Cardiac Fibroblast (VCF) cell therapy that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies. MTC001 uses a simple hospital-to-manufacturing-site-to-hospital workflow; VCF is collected from a cardiac biopsy in a minimally invasive manner. The company says VCF has significant manufacturing and safety advantages over alternative approaches. The $12.7M Series B enables Metcela to initiate Phase I clinical trials in Japan. Metcela intends to use the funds to grow its team and expand its portfolio. Metcela is a clinical-stage biotechnology company focused on developing fibroblast-based cell therapies. Its lead product, MTC001, is a fibroblast-based therapy intended to treat chronic heart failure. Through preclinical research the company identified VCAM-1-positive cardiac fibroblasts (VCFs) that stimulate cardiomyocyte proliferation and improve cardiac function via lymphangiogenesis. Metcela plans to accelerate clinical development of MTC001 and initiate a Phase I clinical trial. The company closed a ¥430m (≈$4m) Series B to support these efforts. Metcela is led by Co-CEOs Takahiro Iwamiya and Kenichi Nogami and recently appointed Kenji Yamada as an outside director.

Participated · Series D · Feb 2014

Regimmune focuses on discovery, development and commercialization of immune regulatory therapeutics to treat allergies, autoimmune diseases and complications of transplantation. Its proprietary reVax platform induces immune tolerance in an antigen-specific manner via pharmacological induction of regulatory T (Treg) cells. The company completed a Phase I study of RGI-2001 for graft-versus-host disease and has initiated a Phase II trial of RGI-2001. Regimmune is developing multiple pipeline programs including the RGI-1000 series for allergy, the RGI-3100 series for type 1 diabetes, products to prevent inhibitor formation in enzyme replacement therapies, and a celiac disease program with undisclosed partners. Led by Haru Morita, the company has operations in Tokyo and a US presence in San Francisco. It intends to use the proceeds from the recent financing to support early-stage product development.